The CLEAN-DUCT / TRITICC-3 trial - Phase IIa, prospective, single arm, open label, non-randomized, multi-center pilot study of durvalumab (MEDI4736) + intraductal radiofrequency ablation (ID-RFA) in extrahepatic cholangiocarcinoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509165-21-00

Acronym

CLEAN-DUCT

Enrollment

Registered

2024-05-15

Start date

2024-08-08

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extrahepatic cholangiocarcinoma (eCCA)

Brief summary

Overall survival rate after 12 months (OS@12)

Detailed description

Progression-free survival (PFS), Overall survival (OS), Safety, Time to cholangitis, Quality of life (QoL)

Interventions

DRUGCISPLATIN

DRUGIMFINZI 50 mg/mL concentrate for solution for infusion.

DRUGGEMCITABINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival rate after 12 months (OS@12)	—

Secondary

Measure	Time frame
Progression-free survival (PFS), Overall survival (OS), Safety, Time to cholangitis, Quality of life (QoL)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026